
-
Hong Kong fans queue for opening of Cristiano Ronaldo exhibition
-
Itoje back as Lions take no chances against ACT Brumbies
-
Stock markets struggle as Trump's tariff deadline looms
-
Nearly 450,000 Afghans left Iran since June 1: IOM
-
North Korea bars Western influencers from trade fair tour
-
Typhoon Danas kills two, injures hundreds in Taiwan
-
Dutch coastal village turns to tech to find lost fishermen
-
Boxer Chavez's appeal against arrest if deported from US rejected: Mexico prosecutor
-
India captain Gill hailed back home after 'brilliant' Test win
-
The making of Australia's mushroom murders
-
Indonesia volcano spews 18-kilometre ash tower
-
Youthful Chelsea ready for Thiago Silva reunion at Club World Cup
-
Australian inquiry cites racism in Indigenous shooting
-
Djokovic wary despite Wimbledon form, dominant Sinner faces Dimitrov
-
Australian woman found guilty of triple murder with toxic mushrooms
-
Indonesia volcano spews 18-kilometre ash tower: agency
-
Trump says to send first tariff letters on Monday
-
The strange case of Evgeniya Mayboroda, Russia's rebel retiree
-
Asian markets drop as Trump's tariff deadline looms
-
Under-strength Brumbies eye 'big opportunity' against Lions
-
Macron to rekindle relationship with Francophile King Charles on UK visit
-
Trump hosts Netanyahu, hopes for Israel-Hamas deal 'this week'
-
Pressed to confess: Japan accused of 'hostage justice'
-
Demna to bow out at Balenciaga in Paris Haute Couture Week
-
Host of internationals in Australia-New Zealand squad to face Lions
-
Egyptian conservators give King Tut's treasures new glow
-
Mexico defeat USA 2-1 to retain CONCACAF Gold Cup
-
Visa's 24/7 war room takes on global cybercriminals
-
BRICS nations slam Trump tariffs, condemn strikes on Iran
-
BioNxt's Sublingual Cladribine Program for MS Ready for Next Phase
-
Guardian Metal Resources PLC Announces Pilot North Tungsten Project Acquired via Staking
-
MLB Nationals fire manager Martinez, GM Rizzo after loss
-
US tariffs to kick in Aug 1, barring trade deals
-
Trump slams former ally Musk's political party as 'ridiculous'
-
Three things we learned from the second England-India Test
-
Norway reach Euro 2025 quarter-finals as Swiss down eliminated Iceland
-
Alcaraz vows to avoid Murray after defeat on golf course
-
Alcaraz finds magic touch at Wimbledon as Sabalenka storms into quarter-finals
-
Run-hungry Gill glad to 'lead by example' as India level England series
-
Rockets confirm arrival of Durant in unprecedented NBA seven-team trade
-
Alcaraz survives Rublev test to stay on course for Wimbledon hat-trick
-
New Zealand's Dixon wins seventh IndyCar Mid-Ohio title
-
US tariffs to kick in Aug 1, barring trade deals: Bessent
-
England consider Archer and Atkinson recall after heavy India defeat
-
Durant deal becomes NBA-record seven-team trade: reports
-
Verstappen laments 'really difficult' Silverstone fifth
-
BRICS nations hit out at Trump tariffs
-
Hansen shoots Norway to brink of Euro 2025 quarter-finals
-
Jennifer Geerlings-Simons becomes Suriname's first woman president
-
Netanyahu says Trump meeting could 'advance' Gaza deal ahead of Doha talks

Baby formula plant linked to US shortage resumes production
Production resumed Saturday at an Abbott Nutrition baby formula plant in the US whose closure helped fuel a crippling nationwide shortage.
The facility in Sturges, Michigan has met initial government sanitary requirements for reopening, the company said in a statement.
The plant shut down in February after the death of two babies, and issued a product recall amid concerns over bacteria contamination.
Shortages of specialized formula were particularly worrying to parents of infants with allergies or with certain metabolic conditions.
Concerns became so acute that President Joe Biden met this week with infant food executives and said his administration was doing everything it could to help.
Abbott said Saturday that it was restarting production of its EleCare formula and that the product should be back on store shelves around June 20.
"We're also working hard to fulfill the steps necessary to restart production of Similac and other formulas," Abbott said.
"We will ramp production as quickly as we can while meeting all requirements."
The United States has been struggling with the shortages for months.
Initially caused by supply chain blockages and a lack of workers due to the pandemic, the shortage was exacerbated when Abbott closed its Sturges plant.
Regulators forced the shutdown amid complaints the plant did not adequately protect against contamination from bacteria.
"Frankly, the inspection results were shocking," FDA chief Robert Califf said last month.
There was standing water in key equipment "that present the potential for bacterial contamination," leaks in the roof and a lack of basic hygiene facilities, he said.
But Abbott officials, while apologizing for the shortage, have said there is no conclusive evidence linking the formula to infant illnesses or deaths.
Abbott's Michigan plant is one of the largest formula factories in the United States.
D.Cunningha--AMWN